Fortress Biotech Inc. (FBIO)

0.90
0.01 1.20
NASDAQ : Health Technology
Prev Close 0.91
Open 0.91
Day Low/High 0.90 / 0.95
52 Wk Low/High 0.87 / 5.54
Volume 46.96K
Avg Volume 245.30K
Exchange NASDAQ
Shares Outstanding 54.34M
Market Cap 52.45M
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Mustang Bio Announces Key Leadership Appointments

Mustang Bio Announces Key Leadership Appointments

Sadik Kassim, Ph.D., appointed Chief Scientific Officer and Knut Niss, Ph.D., named Chief Technology Officer

Avenue Therapeutics Reports Fourth Quarter And Full Year 2017 Financial Results And Recent Corporate Highlights

Avenue Therapeutics Reports Fourth Quarter And Full Year 2017 Financial Results And Recent Corporate Highlights

-- Expect to Report Topline Data from Phase 3 Trial of IV Tramadol in Patients Following Bunionectomy Surgery in 2Q18 --

Fortress Biotech Forms Subsidiary Tamid Bio To Develop Novel AAV Gene Therapies In Orphan Diseases With Unmet Medical Needs

Fortress Biotech Forms Subsidiary Tamid Bio To Develop Novel AAV Gene Therapies In Orphan Diseases With Unmet Medical Needs

Tamid enters exclusive licensing deal with UNC-Chapel Hill for three preclinical gene therapy product candidates

Mustang Bio Announces MB-102 Data Selected For Oral Presentation At 59th American Society Of Hematology Annual Meeting

Mustang Bio Announces MB-102 Data Selected For Oral Presentation At 59th American Society Of Hematology Annual Meeting

Research partner City of Hope to present initial Phase 1 data in acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm  

TheStreet Quant Rating: D (Sell)